NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Based on PACER filings(11 documents ) posted 2/28/23 ( see https://www.courtlistener.com below), since 12/1/22 when the nwbo lawsuit was filed against Citadel, Citadel's law firm has been submitting pleadings to Judge Gabriel Gorenstein for the nwbo compliant to be dismissed . On 2/27/23 , the Judge reiterated to Citadel a defendant's response extension to 3/20/23 ; 4/5/23 had been requested . It is interesting that Citadel maligns the data calculations in the JAMA paper , which happens to be the most read JAMA Oncology paper ever (65,000 reads to date) . Citadel's lawyer cites Feuerstein(STAT NEWS) and Sun(MOTLEY FOOL) commentary that the DC VAX L trial failed. See links below.MIA, MAA, and NICE approvals in the U.K. could prove wrong these two commentators before the Citadel response is filed by 3/20/23.

https://www.courtlistener.com/docket/66579590/northwest-biotherapeutics-inc-v-canaccord-genuity-llc/ (11 documents)



https://twitter.com/hoffmann6383/status/1630624757182808080

https://twitter.com/hoffmann6383/status/1630597838756360194

https://storage.courtlistener.com/recap/gov.uscourts.nysd.590344/gov.uscourts.nysd.590344.78.1.pdf

https://www.statnews.com/2022/11/21/northwest-bio-study-of-cancer-vaccine-still-falls-short/

Sun, Zhiyuan, “3 Biotechs to Avoid Like the Plague in July,” The Motley Fool, July 6, 2021, ( https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/ )

(NWBO-sponsored article in JAMA Oncology, apparently showing positive clinical results, was “derived from an untrustworthy, post-hoc analysis that was implemented and conducted after the study had already been completed”)

https://twitter.com/Dave46217976/status/1630900298586767361



12/6/22 letter from Citadel attorney to NWBO attorney. "As an example, a May 10, 2022 article from STAT describes the drug as a “failure” and points out that “ [o]verall, patients treated with DCVax had a 10% higher risk of tumor progression compared to placebo—an outcome that is the antithesis of what’s required from any effective cancer treatment.” Supra, n. 1; see also Feuerstein, Adam, “Northwest Bio Study of Brain Cancer Vaccine Still Falls Short,” STAT, November 21, 2022, (available at https://www.statnews.com/2022/11/21/northwest-bio-study-of-cancer-vaccine-still-falls-short/) (NWBO-sponsored article in JAMA Oncology, apparently showing positive clinical results, was “derived from an untrustworthy, post-hoc analysis that was implemented and conducted after the study had already been completed”); Sun, Zhiyuan, “3 Biotechs to Avoid Like the Plague in July,” The Motley Fool, July 6, 2021, (available at https://www.fool.com/investing/2021/07/06/3- biotechs-to-avoid-like-the-plague-in-july/)"


December 6, 2022 VIA E-MAIL [e-mail] Laura H. Posner Cohen Milstein Sellers & Toll PLLC 88 Pine Street, 14th Floor New York, New York 10005 Re: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC et al, No. 1:22-cv-10185 (S.D.N.Y.): Notice Pursuant to Fed. R. Civ. P. 11 Dear Ms. Posner: We write on behalf of our client Citadel Securities LLC (“Citadel Securities”) to advise you that the Complaint that you and your client, Northwest Biotherapeutics Inc. (“NWBO”), have filed against Citadel Securities in the above-referenced action is frivolous and lacks any colorable or good-faith basis. It is apparent that NWBO’s struggles in the market are attributable to, among other things, the highly disappointing results from a recent late-stage clinical trial of its brain cancer vaccine. As one independent observer described those results, “the failure of Northwest Bio’s brain cancer vaccine is now in the open,” and “[t]he treatment’s data are as bad as expected — performing worse than a placebo.”1 It is equally apparent that there is no legal or factual basis for NWBO’s allegations of market manipulation by Citadel Securities. NWBO’s claims are a brazen attempt to harass and scapegoat Citadel Securities and to distract shareholders from NWBO’s obvious corporate failures. Our client demands that you and NWBO withdraw the Complaint as against Citadel Securities. Rule 11(b) provides in relevant part that an attorney filing a pleading with a court is certifying that to the best of that attorney’s knowledge, formed after a reasonable inquiry, “(1) it is not being presented for any improper purpose, such as to harass, cause unnecessary delay, or needlessly increase the cost of litigation; (2) the claims, defenses, and other legal contentions are 1 Feuerstein, Adam, “It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open,” STAT, May 10, 2022 (available at https://www.statnews.com/2022/05/10/it-took-years-but-the-failure-and-futilityof-northwest-bios-brain-cancer-vaccine-is-now-in-the-open/) (emphases added). Case 1:22-cv-10185-GHW-GWG Document 78-1 Filed 02/28/23 Page 2 of 5 2 warranted by existing law or by a nonfrivolous argument for extending, modifying, or reversing existing law or for establishing new law; [and] (3) the factual contentions have evidentiary support or, if specifically so identified, will likely have evidentiary support after a reasonable opportunity for further investigation or discovery.” Fed. R. Civ. P. 11(b)(1)-(3). A pleading violates Rule 11 “where, after reasonable inquiry, a competent attorney could not form a reasonable belief that the pleading is well-grounded in fact and warranted by existing law[.]” Abdelhamid v. Altria Group, Inc., 515 F. Supp. 2d 384, 391 (S.D.N.Y. 2007). NWBO’s Complaint contains allegations so frivolous and unsupported by law or fact that they violate Rule 11(b) and must be withdrawn. First, your Complaint ignores that a significant percentage of Citadel Securities’ trading is carried out on behalf of its retail broker-dealer clients, not on its own behalf. By your own admission, Citadel Securities “executes approximately 35% of all U.S.-listed retail volume, making it the industry’s top wholesale market maker.” Compl. ¶ 17. Part of market making is routing orders on behalf of clients. Any orders placed on behalf of a client were obviously intended to service the client at their direction, not to “manipulate” share prices, and therefore cannot support allegations that Citadel Securities engaged in spoofing. For instance, in the two examples set forth in the Complaint (see ¶¶ 74-79, 213-218), Citadel Securities has confirmed that its records indicate that all of the relevant orders during the alleged time period were on behalf of clients. Cohen Milstein is an experienced securities law firm that is presumably aware that market makers buy and sell securities on behalf of clients. And yet the Complaint never acknowledges that Citadel Securities—the largest such U.S. firm—frequently places trades on behalf of its clients, rather than for its own account. Your blatant failure to acknowledge that Citadel Securities typically trades to service its clients fatally undermines your allegations of intent—and underscores your bad faith in bringing this lawsuit. Second, the Complaint impermissibly engages in group pleading. The Complaint routinely brings claims against “Defendants” in general—or against Defendants taken as an average or a median or some other statistical grouping—which would not survive notice pleading review, much less the heightened scrutiny of Rule 9(b) for pleadings alleging fraud. See Dulsky v. Worthy, 2013 WL 4038604, at *5 (S.D.N.Y. July 30, 2013) (“Rule 9(b) is not satisfied by filing a complaint in which defendants are clumped together in vague allegations.”); cf. Compl. ¶¶ 63-64 (generic allegations as to undifferentiated “Defendants”); id. ¶¶ 58, 65, 67 (allegations as to “total” shares purchased by all Defendants); id. ¶¶ 251-252 (allegations as to the “median” of all Defendants’ transactions); id. ¶¶ 69-70, 73 (allegations as to “average” conduct by Defendants). Allegations regarding purported actions taken by “Defendants” without specific allegations regarding Citadel Securities will not satisfy Rule 9(b) scrutiny as to Citadel Securities. Third, the Complaint completely fails to make any particularized, non-conclusory allegations of scienter or fraudulent intent as to Citadel Securities. The particularized allegations of intent pertain only to a defendant other than Citadel Securities. Compl. ¶¶ 237-240 (allegations of intent as to GTS Securities LLC). As to scienter, the Complaint alleges 15 (duplicative) reasons why a court should infer scienter. Compl. ¶¶ 241-258. And yet none of the allegations of scienter pertain in any particularized way to any Defendant, and Citadel Securities is not even mentioned. The Complaint must therefore be dismissed as to Citadel Securities. See Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308, 324 (2007) (a “strong inference” of scienter “must be more Case 1:22-cv-10185-GHW-GWG Document 78-1 Filed 02/28/23 Page 3 of 5 3 than merely ‘reasonable’ or ‘permissible’—it must be . . . cogent and at least as compelling as any opposing inference one could draw from the facts alleged.”). Fourth, NWBO fails to allege any economic loss or that the alleged conduct by Citadel Securities proximately caused any harm to NWBO. Significantly, the Complaint does not allege that any sales by NWBO were executed after the alleged spoofing. See In re Merrill, Bofa, and Morgan Stanley Spoofing Litig., 2021 WL 827190, at *12 (S.D.N.Y. Mar. 4, 2021) (dismissing claims absent allegations that “on the dates there were spoof[ed] trades, [plaintiffs] traded after the spoof”). Nor does the Complaint even allege that NWBO sold any shares on May 10, 2022, let alone that it sold shares after any alleged “baiting orders.” See Gamma Traders - I LLC v. Merrill Lynch Commodities, Inc., 41 F.4th 71, 81 (2d Cir. 2022) (dismissing for failure to allege damages where plaintiff “never actually alleges when its own trades took place”). Fifth, the statutory claims are barred in part by the applicable statute of limitations. Plaintiff’s Exchange Act claims are restricted by a two-year statute of limitations. 28 U.S.C. § 1658(b). Your Complaint, which was filed on December 1, 2022, seeks damages for a “Relevant Period,” extending back to December 5, 2017. Compl. ¶ 1. The vast majority of the trades that the Complaint attributes to Citadel Securities occurred prior to December 1, 2020 and therefore cannot serve as a predicate for claims arising under the Exchange Act. Your decision to include claims so clearly barred under the relevant statute of limitations is additional evidence of your bad faith in bringing this action. This is far from an exhaustive list of why the Complaint is frivolous and must be withdrawn as to Citadel Securities immediately. The true basis of NWBO’s Complaint appears to be the generalized grievance that “[d]espite the string of encouraging news about its lead product, NWBO’s share price has not followed suit.” Compl. ¶ 6. NWBO needs a scapegoat, and it has cast Citadel Securities—and others—in this role. Such allegations cannot, as a matter of law, form the basis for claims of fraud. See ATSI Communications, Inc. v. Shaar Fund, Ltd., 493 F.3d 87, 103 (2d Cir. 2007) (market manipulation may not be inferred from “stock’s negative reaction to positive news”). Moreover, such claims are not well-grounded in fact. Although NWBO cherry picks for the Complaint an article favorably reviewing the results of the Phase 3 clinical trial of DCVax-L (Compl. ¶ 41), even a cursory search turns up significant negative press about this and other clinical results. As an example, a May 10, 2022 article from STAT describes the drug as a “failure” and points out that “ [o]verall, patients treated with DCVax had a 10% higher risk of tumor progression compared to placebo—an outcome that is the antithesis of what’s required from any effective cancer treatment.” Supra, n. 1; see also Feuerstein, Adam, “Northwest Bio Study of Brain Cancer Vaccine Still Falls Short,” STAT, November 21, 2022, (available at https://www.statnews.com/2022/11/21/northwest-bio-study-of-cancer-vaccine-still-falls-short/) (NWBO-sponsored article in JAMA Oncology, apparently showing positive clinical results, was “derived from an untrustworthy, post-hoc analysis that was implemented and conducted after the study had already been completed”); Sun, Zhiyuan, “3 Biotechs to Avoid Like the Plague in July,” The Motley Fool, July 6, 2021, (available at https://www.fool.com/investing/2021/07/06/3- biotechs-to-avoid-like-the-plague-in-july/) (FDA halted NWBO clinical trial for two years for reasons that NWBO failed to explain). NWBO has also disclosed “material weaknesses” in its Case 1:22-cv-10185-GHW-GWG Document 78-1 Filed 02/28/23 Page 4 of 5 4 securities filings, with “insufficient effort at remediation” over a period of twelve years. SEC Press Release, SEC Files Settled Action Against Biotechnology Company Related To Unremediated Material Weaknesses Spanning Twelve Years, File No. 3-19582, Oct. 10, 2019 (available at https://www.sec.gov/enforce/34-87281-s). NWBO’s Complaint is nothing more than a transparent attempt to distract from the dismal results of its drug development, its management failures, SEC charges for financial reporting lapses, and lawsuits from its own shareholders. NWBO has no one to blame but itself—and certainly not Citadel Securities. It is clear that neither you nor your client conducted any reasonable pre-filing inquiry into the factual contentions regarding Citadel Securities’ alleged conduct as described in the Complaint, and that instead you and your client filed groundless claims against Citadel Securities for an improper purpose. Accordingly, the claims against Citadel Securities violate Rule 11(b). We therefore demand that NWBO immediately withdraw its claims against Citadel Securities. Please convey your client’s decision to us by 5 p.m. E.T. on December 9, 2022. If your client does not dismiss its claims against Citadel Securities, please be advised that Citadel Securities intends to move for sanctions against you and your client. Please also be advised that we are aware that you and you firm provided a draft of the Complaint to members of the press prior to filing and have been making defamatory statements regarding Citadel Securities to the public. Citadel Securities is evaluating its legal rights regarding your conduct. Citadel Securities reserves all rights, including rights related to your defamatory statements and the right to seek attorneys’ fees for any further defense of this frivolous action. Sincerely, /s/ William A. Burck William A. Burck

On December 1, 2022, Cohen Milstein, on behalf of plaintiff Northwest Biotherapeutics (OTCQB: NWBO), filed a securities lawsuit in the U.S. District Court for the Southern District of New York, alleging that market makers Canaccord Genuity LLC, Citadel Securities LLC, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp., Susquehanna International Group LLP, Virtu Americas LLC, deliberately engaged in repeated manipulative spoofing of NWBO’s stock from December 5, 2017 – August 1, 2022, causing NWBO to issue more than 49 million shares at artificially depressed prices in violation of Section 10(b), Rule 10b-5 and Section 9(a)(2) of the Securities Exchange Act of 1934. Their alleged actions also constitute as fraud under New York state common law.

Case Background
NWBO is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy, through a proprietary manufacturing technology which enables the Company to produce a personalized vaccine in an efficient and cost-effective manner. The Company’s lead product, DCVax®-L, received the first-ever “Promising Innovative Medicine” designation under the United Kingdom’s “Early Access to Medicines Scheme” on September 16, 2014.

NWBO recently completed a 331-patient Phase 3 clinical trial of DCVax-L in the United States, Canada, U.K., and Germany for patients with glioblastoma multiforme (“GBM”), the most aggressive and lethal form of brain cancer.

On May 10, 2022, positive top-line results from the clinical trial were presented at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences, showing that DCVax-L had reached both its primary and its secondary endpoints with statistical significance under the Statistical Analysis Plan for the Phase 3 trial. The survival data of the trial was promising; no other GBM trial in decades has shown such improvements in both median survival and the “long tail” of extended survival in both newly diagnosed and recurrent (late stage) GBM patients.

Most recently, on November 17, 2022, JAMA Oncology, the highly respected, peer-reviewed cancer journal, reported that the trial results demonstrated that DCVax-L was “associated with a clinically meaningful and statistically significant extension of overall survival” and “also had an excellent safety profile and noteworthy tails of long-term survival curves.”

Despite the string of encouraging news about its lead product, NWBO’s share price has not followed suit. Quite the opposite actually—and that is not by chance. Rather, because of Defendants’ spoofing, NWBO’s share price has dropped.

Spoofing is a form of market manipulation that, in this case, was accomplished by placing “Baiting Orders” in the Limit Order Book2 or Inter-Dealer Quotation System (“IDQS”)3 that are not intended to be executed and have no legitimate economic purpose. The purpose of these Baiting Orders is to create a false illusion of market interest (either positive or negative) that will generate a response from other market participants that the spoofers can use to their advantage. For example, if the goal of the spoofing scheme is to drive the price down, the spoofer enters Baiting Orders to sell, to create an appearance of a downward trending market, which will then bait other market participants into entering their own sell orders to minimize or avoid suffering losses. Shortly thereafter, the spoofer will place orders to buy, or “Executing Purchases,” which are intended to be executed against the other market participants’ sell orders at the lower artificial prices prompted by the false Baiting Orders to sell. Immediately after placing these Executing Purchases to buy, the spoofer then cancels all of the Baiting Orders to sell, which completes the profitable spoofing cycle.

This scheme can be used multiple times during a trading day, and then repeated throughout a protracted trading period. To maximize the speed of their market access and execution of their trading strategies, spoofers typically utilize algorithmic trading programs through high-frequency trading computer systems which enable thousands of Baiting Orders to be placed in a matter of seconds and sometimes milliseconds.

During the Relevant Period, Defendants engaged in spoofing to manipulate the price of NWBO shares on OTC Link LLC and NYSE ARCA Global OTC, thus creating an imbalance in the market for NWBO shares and inducing other market participants to buy or sell at artificial prices. In order to carry out their spoofing scheme, Defendants placed tens of millions of Baiting Orders and executed millions of orders at manipulated prices during the Relevant Period. Indeed, Defendants engaged in spoofing on 395 of 1,171—or nearly 34%—of the trading days during the Relevant Period.

Plaintiff NWBO sold over 49 million shares at manipulated prices as a result of Defendants’ actions. By repeatedly and brazenly manipulating the market through their spoofing, Defendants directly impacted the price of NWBO’s shares in the market, causing Plaintiff significant losses as it sold millions of shares of NWBO stock at artificially depressed prices.

Case style: Northwest Biotherapeutics, Inc. v. Canaccord Genuity LLC, et al., Case No. 1:22-cv-10185, United States District Court for the Southern District of New York
CASE DOCUMENTS
RELATED PROFESSIONALS
RELATED NEWS & EVENTS




Cohen Milstein Files Lawsuit on Behalf of Northwest Biotherapeutics Against Major Market Makers for Market Manipulation

NEW YORK, NY / ACCESSWIRE / December 1, 2022 / Today, Northwest Biotherapeutics (OTCQB:NWBO) filed a lawsuit against some of the largest and most influential market makers in the world, including Citadel Securities LLC, Canaccord Genuity LLC, G1 Execution Services LLC (a subsidiary of Susquehanna International Group), GTS Securities LLC, Virtu Americas LLC (including Knight Securities), Instinet LLC, and Score Priority Corp, alleging repeated manipulation of the company's stock over five years.

Northwest Biotherapeutics, a clinical stage biotechnology company focused on the development of DCVax® personalized cancer vaccines, is alleging that these market makers have been engaging in a deceptive market manipulation tactic known as spoofing, which involves placing huge quantities of sell orders to fool the market into devaluing the company's stock so the market makers can buy at a lower price. The market makers then immediately cancel the sell orders so they can reap profits, in this case to the dismay of current and future cancer patients, as well as at the expense of Northwest Biotherapeutics and its investors. This alleged illegal trading behavior has made it significantly more difficult for the company to raise the funds necessary to bring their cancer treatment to market, where the company believes it has the potential to extend the lives of thousands of patients.

"It's already underhanded to engage in market manipulation, but to do so at the expense of cancer patients, some of whom have no other treatments to place their hopes on, is unconscionable," said Laura Posner, Partner at Cohen Milstein Sellers & Toll PLLC. "We're looking forward to holding these market makers responsible for the harm they have caused, and bringing critical and necessary transparency to these markets."

Based on the detailed data presented in the complaint, one of the most egregious examples of this behavior occurred on May 10, 2022, at the very moment the topline breakthrough results of the Phase 3 clinical trial of DCVax-L to treat glioblastoma, the most common and aggressive form of brain cancer, were being announced at the prestigious New York Academy of Sciences medical conference. Despite the presentation of significant positive data, the company alleges that during and after the announcement the defendants engaged in extensive spates of spoofing, forcing the company's stock price down. In a market free from manipulation, the market response should have been strongly positive, not dramatically negative, in response to the positive news. Instead, the result was a $1.6 billion loss in market cap, with the share price dropping from the $2.05 high on May 9 to a low of 36.4 cents on May 10, 2022-a staggering decline of 82%.

Earlier this month, Northwest Biotherapeutics announced the results of this innovative clinical trial for DCVax-L in the prestigious JAMA Oncology journalin a peer reviewed article authored by over 70 brain surgeons and oncologists. The trial results showed that the vaccine was associated with a statistically significant and clinically meaningful life extension for the first time in many years in both newly diagnosed and recurrent glioblastoma, with the potential to more than double 5-year survival, and with almost no serious adverse event side effects. The company believes that this breakthrough vaccine technology may also pave the way for treatments in patients suffering from multiple types of solid tumor cancers.

The spoofing episodes against the company are alleged to have taken place repeatedly over a nearly five-year stretch, sometimes multiple times a day. Northwest Biotherapeutics alleges that it sold over 49 million shares at manipulated and devalued prices as a result of the market makers' actions. The company believes that the market makers directly impacted the price of Northwest Biotherapeutics' shares in the market by repeatedly and brazenly manipulating the market through their spoofing, causing Northwest Biotherapeutics to suffer significant losses as it sold millions of shares at artificially depressed prices and was slowed in bringing its encouraging drugs to market.

Northwest Biotherapeutics is represented by national law firm Cohen Milstein Sellers & Toll PLLC.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company specializing in developing cutting-edge cancer vaccines that are designed to treat a wide range of solid tumor cancers more effectively than the current treatments on the market and without the side effects of chemotherapy. The company has a broad platform technology for DCVax® dendritic cell-based vaccines, including DCVax®-L for operable tumors and DCVax®-Direct for inoperable tumors. The company's proprietary manufacturing technology allows efficient and cost-effective production of these innovative vaccines, with the full set of multi-year doses produced in one manufacturing batch and then stored frozen in single doses, making the treatment "off the shelf" throughout the treatment regimen while also being fully personalized.

About Cohen Milstein Sellers & Toll

Cohen Milstein Sellers & Toll PLLC is recognized as one of the premier law firms in the country handling major, complex plaintiff-side litigation. With more than 100 attorneys, Cohen Milstein has offices in Washington, D.C.; Chicago, Ill.; New York, N.Y.; Palm Beach Gardens, Fla.; Philadelphia, Pa.; and Raleigh, N.C. For additional information, visit www.cohenmilstein.com or call 202.408.4600.

Contact:

Tess Roy, [e-mail], 561-596-6443

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE: Cohen Milstein Sellers & Toll PLLC
https://twitter.com/fireman02360/status/1630925347494543363

Bright Boy

Member Level
Re: biosectinvestor post# 572159

Tuesday, February 28, 2023 9:22:57 PM

Post#
572202
of 572364
People!! Listen up!!!!

The second inspection was simply a congratulatory visit!!! How doI know??? Well,let's just say I heard rumors from a few people.All the money in the world that;s lined up by Kenny and friends against Northwest to find something wrong with the process was unsuccessful !!! If they had found even the slightest problem, they would have ballooned it into a mountain the size of Mt. Everest!!! and it would have been "front page, above the fold" on every major newspaper in the US!!

Kenny was successful in buying the US congress for $100 million and directing their attentions away from illegal market operations, but that's only temporary, because Northwest' lawsuit will change market operations forever!! Kenny failed miserably when trying to influence a small group of dedicated people in the British MHRA. I'll tell you an absolute fact !!! Major biotech companies go to the UK/MHRA before the FDA, because they know they'll be reviewed by a group of people that are dedicated to delivering innovative treatments to patients in need, free from influence by the "color of money" !!!

So, hopefully my comments have provided a certain "peace of mind" regarding Northwest' receipt of both a manufacturing license and marketing license and the follow on interests of an institutional investor and subsequent uplist, all of which ill happen very quickly!!! My very best guess is thayt we will have the MIA before the weekend!!
Cheers,

BB